Trial reportAmerican journal of obstetrics and gynecology2018
Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
Trial report in American journal of obstetrics and gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA-A secondary analysis.Neurourology and urodynamics · 2023Trial
- Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.Advances in therapy · 2026Review
- Clinical and urodynamic indicators of non-response to OnabotulinumtoxinA in idiopathic overactive bladder.The Canadian journal of urology · 2026Article
- Intradetrusor OnabotulinumtoxinA Safety and Efficacy in Patients 80 Years and Older: A Retrospective Cohort Study.International urogynecology journal · 2026Article
- The Association Between Blood Lead Levels and Urgency Urinary Incontinence Among Adult Females: A Retrospective Study Based on NHANES 2005-2020.Biological trace element research · 2025Article
- Outcomes following intradetrusor onabotulinumtoxinA in a national cohort of nursing home residents.BJUI compass · 2025Article
- Examining the Role of Frailty on Treatment Patterns and Complications Among Older Women Undergoing Procedure-Based Treatment for Urinary Incontinence.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Evaluation and management of urinary incontinence in nursing home residents: unique considerations for an at-risk population.Gynecology and pelvic medicine · 2024Review
- Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment.Toxins · 2023Article
- Effect of Neuro-Adaptive Electrostimulation Therapy versus Sham for Refractory Urge Urinary Incontinence Due to Overactive Bladder: A Randomized Single-Blinded Trial.Journal of clinical medicine · 2023Article
- Third-line therapy for overactive bladder in the elderly: Nuances and considerations.Neurourology and urodynamics · 2022Review
- Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.Neurourology and urodynamics · 2022Article
- Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?International urogynecology journal · 2021Article
- Feasibility of Real-Time Conditional Sacral Neuromodulation Using Wireless Bladder Pressure Sensor.IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society · 2021Article
- Relationship Between Blood Glucose and Hemoglobin A1c Levels and Urinary Incontinence in Women.International journal of general medicine · 2021Article
- Continence: Bowel and Bladder and Physical Function Decline in Women.Current geriatrics reports · 2020Article
- Botulinum Toxin A: A Review of Potential Uses in Treatment of Female Urogenital and Pelvic Floor Disorders.Ochsner journal · 2020Review
- Dilemmas in Management of the Geriatric Bladder.Current bladder dysfunction reports · 2019Article
- Variation in bony landmarks and predictors of success with sacral neuromodulation.International urogynecology journal · 2019Article
- The impact of frailty on treatment for overactive bladder in older adults.Neurourology and urodynamics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWomen with refractory urgency urinary incontinence (ie, unresponsive to behavioral and pharmacological interventions) are treated with onabotulinumtoxinA or sacral neuromodulation.
objectiveThe objective of the study was to compare treatment efficacy and adverse events in women <65 and ≥65 years old treated with onabotulinumtoxinA or sacral neuromodulation. STUDY
designThis study was a planned secondary analysis of a multicenter, randomized trial that enrolled community-dwelling women with refractory urgency urinary incontinence to onabotulinumtoxinA or sacral neuromodulation treatments. The primary outcome was a change in mean daily urgency urinary incontinence episodes on a bladder diary over 6 months. Secondary outcomes included ≥75% urgency urinary incontinence episode reduction, change in symptom severity/quality of life, treatment satisfaction, and treatment-related adverse events.
resultsBoth age groups experienced improvement in mean urgency urinary incontinence episodes per day following each treatment. There was no evidence that mean daily urgency urinary incontinence episode reduction differed between age groups for onabotulinumtoxinA (adjusted coefficient, -0.127, 95% confidence interval, -1.233 to 0.979; P = .821) or sacral neuromodulation (adjusted coefficient, -0.698, 95% confidence interval, -1.832 to 0.437; P = .227). Among those treated with onabotulinumtoxinA, women <65 years had 3.3-fold greater odds of ≥75% resolution than women ≥65 years (95% confidence interval, 1.56 -7.02). Women <65 years had a greater reduction in Overactive Bladder Questionnaire Short Form symptom bother scores compared with women ≥65 years by 7.49 points (95% confidence interval, -3.23 to -11.74), regardless of treatment group. There was no difference between quality of life improvement by age. Women ≥65 years had more urinary tract infections following onabotulinumtoxinA and sacral neuromodulation (odds ratio, 1.9, 95% confidence interval, 1.2-3.3). There was no evidence of age differences in sacral neuromodulation revision/removal or catheterization following onabotulinumtoxinA treatment.
conclusionYounger women experienced greater absolute continence, symptom improvement, and fewer urinary tract infections; both older and younger women had beneficial urgency urinary incontinence episode reduction, similar rates of other treatment adverse events, and improved quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.